Macular Dystrophy and Cone-Rod Dystrophy Caused by Mutations in the RP1 Gene: Extending the RP1 Disease Spectrum.
journal contributionposted on 2019-06-14, 15:43 authored by SK Verbakel, RAC van Huet, AI den Hollander, MJ Geerlings, E Kersten, BJ Klevering, CCW Klaver, AS Plomp, NL Wesseling, AAB Bergen, K Nikopoulos, C Rivolta, Y Ikeda, K-H Sonoda, Y Wada, CJF Boon, T Nakazawa, CB Hoyng, KM Nishiguchi
Purpose: To describe the clinical and genetic spectrum of RP1-associated retinal dystrophies. Methods: In this multicenter case series, we included 22 patients with RP1-associated retinal dystrophies from 19 families from The Netherlands and Japan. Data on clinical characteristics, visual acuity, visual field, ERG, and retinal imaging were extracted from medical records over a mean follow-up of 8.1 years. Results: Eleven patients were diagnosed with autosomal recessive macular dystrophy (arMD) or autosomal recessive cone-rod dystrophy (arCRD), five with autosomal recessive retinitis pigmentosa (arRP), and six with autosomal dominant RP (adRP). The mean age of onset was 40.3 years (range 14-56) in the patients with arMD/arCRD, 26.2 years (range 18-40) in adRP, and 8.8 years (range 5-12) in arRP patients. All patients with arMD/arCRD carried either the hypomorphic p.Arg1933* variant positioned close to the C-terminus (8 of 11 patients) or a missense variant in exon 2 (3 of 11 patients), compound heterozygous with a likely deleterious frameshift or nonsense mutation, or the p.Gln1916* variant. In contrast, all mutations identified in adRP and arRP patients were frameshift and/or nonsense variants located far from the C-terminus. Conclusions: Mutations in the RP1 gene are associated with a broad spectrum of progressive retinal dystrophies. In addition to adRP and arRP, our study provides further evidence that arCRD and arMD are RP1-associated phenotypes as well. The macular involvement in patients with the hypomorphic RP1 variant suggests that macular function may remain compromised if expression levels of RP1 do not reach adequate levels after gene augmentation therapy.
Supported by the Japan Agency for Medical Research and Development (TN, JP17lk1403004;KMN 17ek0109213h0002). The research leading to these results has received funding from the European Research Council under the European Union's Seventh Framework Programme (FP/2007–2013)/ERC Grant Agreement n. 310644 (MACULA), the European Union's Horizon 2020 research and innovation program under Grant Agreement no. 634479 (EYE-RISK), the Maculafonds No. MF-2018–58_FZ, and The Swiss National Science Foundation (Grant No. 176097). The funding organizations had no role in the design or conduct of this research.
CitationInvestigative Ophthalmology & Visual Science, 2019, 60 (4), pp. 1192-1203
Author affiliation/Organisation/COLLEGE OF LIFE SCIENCES/Biological Sciences/Genetics and Genome Biology
- VoR (Version of Record)